Compare Cognizant Technology Solutions Corp (CTSH) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs GSK plc — how do they compare? Cognizant Technology Solutions Corp trades at $59.2 (market cap $27.03B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 3.4× Cognizant Technology Solutions Corp's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and GSK plc for 93 Days on average.
| CTSH | GSK | |
|---|---|---|
Market Cap | $27.03B | $91.88B |
Volume | 9,883,888 | 7,730,529 |
Sector | Technology | Health |
52-Week High | $86.70 | $61.18 |
52-Week Low | $38.73 | $43.24 |
Typical Hold Time | 57 Days | 93 Days |
Enterprise Value | $28.08B | $111.88B |
Dividend Yield | 2.2% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $60.01, up 5.15% over 24 hours, reflecting strong momentum near its pivot point of $58. The stock shows bullish technical signals with moving averages supporting an uptrend. Fundamentally, CTSH maintains solid profitability with a 10.26% net margin and a modest P/E of 12.88. Recent earnings beats in Q4 2025 and Q1 2026 were offset by a Q2 2026 miss, with Q3 2026 results pending. Positive news includes AI-driven partnerships and employer awards, enhancing its growth narrative.
CTSH presents a balanced investment case with a consensus price target of $64.25 offering ~7% upside. Strengths include stable cash flow and undervaluation relative to peers, but risks involve IT spending pressures from AI disruption and competitive threats. Analyst sentiment is evenly split between Buy and Hold, indicating cautious optimism. The stock's outlook hinges on execution in AI services and sustaining margin discipline amid industry headwinds.
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
